Investment Bank Mizuho Initiates Coverage of Exact Sciences with Buy Rating | GenomeWeb

NEW YORK (GenomeWeb News) – Mizuho Securities USA has initiated coverage of Exact Sciences with a Buy rating and a $13 price target.

The Madison, Wis.-based firm is developing the Cologuard test, a stool-based DNA test for colorectal cancer screening. Mizuho analyst Peter Lawson said in a note that there is a "large untapped revenue opportunity available to Cologuard of over $1.2 billion in the US with limited competition."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.